Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × camrelizumab × Clear all

Phase

Phase 1/2 2 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 1 Pancreatic Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Breast Neoplasms 1 Advanced Solid Tumor 1 Adenocarcinoma 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Ciprofloxacin 2 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1 pertuzumab 1 pembrolizumab 1 osimertinib 1 netupitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡